Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma
Status:
Completed
Trial end date:
2018-02-16
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of bortezomib when given
together with melphalan, and total-body irradiation before stem cell transplant and to see
how well it works in treating patients with multiple myeloma. Giving chemotherapy and
total-body irradiation before a stem cell transplant stops the growth of cancer cells by
stopping them from dividing or killing them. The stem cells that were collected from the
patient's blood or bone marrow are returned to the patient to replace the blood-forming cells
that were destroyed by the chemotherapy and total-body irradiation.